NEW YORK, NY / ACCESSWIRE / September 6, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Activision Blizzard, Inc. (NASDAQ:ATVI)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/activision-blizzard-inc-loss-submission-form-2?prid=19392&wire=1
Lead Plaintiff Deadline: October 4, 2021
Class Period: August 4, 2016 - July 27, 2021
Allegations against ATVI include that: (1) Activision Blizzard discriminated against women and minority employees; (2) Activision Blizzard fostered a pervasive "frat boy" workplace culture that continues to thrive; (3) numerous complaints about unlawful harassment,
discrimination, and retaliation were made to human resources personnel and executives which went unaddressed; (4) the pervasive culture of harassment, discrimination, and retaliation would result in serious impairments to Activision Blizzard's operations; (5) as a result of the foregoing, the Company was at greater risk of regulatory and legal scrutiny and enforcement, including that which would have a material adverse effect; (6) Activision Blizzard failed to inform shareholders that the California Department of Fair Employment and Housing had been investigating Activision Blizzard for harassment and discrimination; and (7) as a result, Defendants' statements about Activision Blizzard's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Iterum Therapeutics Plc (NASDAQ:ITRM)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19392&wire=1
Lead Plaintiff Deadline: October 4, 2021
Class Period: November 30, 2020 - July 23, 2021
Allegations against ITRM include that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Annovis Bio, Inc. (NYSE:ANVS)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/annovis-bio-inc-loss-submission-form?prid=19392&wire=1
Lead Plaintiff Deadline: October 18, 2021
Class Period: May 21, 2021 - July 28, 2021
Allegations against ANVS include that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/662860/SHAREHOLDER-ALERT-ATVI-ITRM-ANVS-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
